DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in B-Cell Non-Hodgkin Lymphoma Research. Learn more about our innovative pipeline today! @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook
Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report
- June 2024:- Bayer- A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) – CHRONOS-3. The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.
- June 2024:- ImmPACT Bio– This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy.
- June 2024:- Regeneron Pharmaceuticals– The study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as ‘refractory’) or has returned (also known as ‘relapsed’). The aim of the study is to see how effective the study drug is compared to standard of care (SOC) therapy.
- DelveInsight’s B-Cell Non-Hodgkin Lymphoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for B-Cell Non-Hodgkin Lymphoma treatment.
- The leading B-Cell Non-Hodgkin Lymphoma Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others.
- Promising B-Cell Non-Hodgkin Lymphoma Therapies such as CD19 CAR-T cells, HY004, Glofitamab, Atezolizumab, Obinutuzumab, Copanlisib (Aliqopa, BAY80-6946), Rituximab, Odronextamab, DZD8586, IMPT-314, and others.
Stay informed about the cutting-edge advancements in B-Cell Non-Hodgkin Lymphoma Treatments. Download for updates and be a part of the revolution in care @ B-Cell Non-Hodgkin Lymphoma Clinical Trials Assessment
B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile
Valemetostat: Daiichi Sankyo
Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.
- MB-106: Mustang Bio
MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.
- CB-010: Caribou Biosciences
CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.
- LP-284: Lantern Pharma
LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern’s RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.
Learn more about B-Cell Non-Hodgkin Lymphoma Drugs opportunities in our groundbreaking B-Cell Non-Hodgkin Lymphoma Research and development projects @ B-Cell Non-Hodgkin Lymphoma Unmet Needs
B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in B-Cell Non-Hodgkin Lymphoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatic Tumor Market Drivers and Barriers, and Future Perspectives
Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report
- Coverage- Global
- B-Cell Non-Hodgkin Lymphoma Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others.
- B-Cell Non-Hodgkin Lymphoma Therapies- CD19 CAR-T cells, HY004, Glofitamab, Atezolizumab, Obinutuzumab, Copanlisib (Aliqopa, BAY80-6946), Rituximab, Odronextamab, DZD8586, IMPT-314, and others.
- B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of B-Cell Non-Hodgkin Lymphoma Pipeline on our website @ B-Cell Non-Hodgkin Lymphoma Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- B-Cell Non-Hodgkin Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- B-Cell Non-Hodgkin Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Valemetostat: Daiichi Sankyo
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- CB-010: Caribou Biosciences
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- B-Cell Non-Hodgkin Lymphoma Key Companies
- B-Cell Non-Hodgkin Lymphoma Key Products
- B-Cell Non-Hodgkin Lymphoma- Unmet Needs
- B-Cell Non-Hodgkin Lymphoma- Market Drivers and Barriers
- B-Cell Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
- B-Cell Non-Hodgkin Lymphoma Analyst Views
- B-Cell Non-Hodgkin Lymphoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/